1 January 2025 - The January 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The January issue of the Schedule includes several new/revised listings of note: 

• Adalimumab (Hyrimoz) - new strength
• Olaparib (Lynparza) - new indication
• Risperidone (Risvan) - new formulation
• Talazoparib tosylate (Talzenna) - new medicine

Read Summary of PBS changes